Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821028 · ClinicalTrials.gov registry record · NA
Local Paclitaxel Delivery for SFA Disease
A NA study of Peripheral Arterial Disease and Atherosclerosis, sponsored by University of Oklahoma.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00821028: Completed NA study of Peripheral Arterial Disease and Atherosclerosis, sponsored by University of Oklahoma.
NCT00821028 is a NA study of Peripheral Arterial Disease and Atherosclerosis that has completed, run by University of Oklahoma. The registered enrollment target is 27 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00821028, a NA study of Peripheral Arterial Disease and Atherosclerosis, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.
Conditions Studied
Interventions
- DRUG Paclitaxel
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-04 |
| Phase | NA |
What the finished NCT00821028 record still lists
NCT00821028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel is the first listed.
NCT00821028 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00821028 about?
NCT00821028 is a clinical study titled "Local Paclitaxel Delivery for SFA Disease". To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.
What is the current status of trial NCT00821028?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2009-01. Estimated completion is 2012-04.
What conditions does trial NCT00821028 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Atherosclerosis, Angioplasty.
What interventions are being tested in trial NCT00821028?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00821028?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00821028 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00821028's enrollment target sits among peer trials
27 60th of 79 higher than 20 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia